Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. Its lead product candidate includes IPI-504 (retaspimycin hydrochloride), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). The company is conducting an international Phase II clinical trial of IPI-504 in combination with Herceptin in patients with HER2-positive metastatic breast cancer; a Phase II clinical trial of IPI-504 in patients with advanced non-small cell lung cancer; and a Phase I clinical trial of IPI-504 in combination with Taxotere in patients with advanced solid tumors. Its products under Phase I clinical trial comprise IPI-493, an orally-delivered inhibitor of Hsp90, in patients with advanced solid tumors; IPI-926 for patients with advanced and/or metastatic solid tumors; and IPI-940, an orally-delivered inhibitor of fatty acid amide hydrolase for the treatment of neuropathic and inflammatory pain. Infinity Pharmaceuticals has strategic alliance agreements with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited; an agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway; and a collaboration agreement with Novartis Institute for BioMedical Research, Inc. to discover, develop, and commercialize drugs targeting Bcl protein family members for the treatment of cancers.

The company is headquartered in Cambridge, Massachusetts.

Type
Public
HQ
Cambridge, US
Founded
2001
Employees
222 (est)-58%
Infinity Pharmaceuticals was founded in 2001 and is headquartered in Cambridge, US

Key People at Infinity Pharmaceuticals

David A. Roth

David A. Roth

Senior Vice President, Clinical Development and Medical Affairs
Margaret A. Read

Margaret A. Read

Vice President, Product Development
Joseph F. McPherson

Joseph F. McPherson

Vice President, Vendor Management/Sourcing and Facilities Operations
Lawrence E. Bloch

Lawrence E. Bloch

Executive Vice President, Chief Financial Officer and Chief Business Officer
Julian Adams

Julian Adams

President, Research and Developmen
Tamyra A. Toole

Tamyra A. Toole

Vice President, Regulatory affairs and Quality Assurance

Infinity Pharmaceuticals Locations

Cambridge, US

Infinity Pharmaceuticals Metrics

Infinity Pharmaceuticals Summary

Market capitalization

$67.6 M

Closing share price

$1.41
Infinity Pharmaceuticals's latest market capitalization is $67.6 M.

Infinity Pharmaceuticals Market Value History

Infinity Pharmaceuticals News

Infinity Pharmaceuticals Company Life

You may also be interested in